trastuzumab emtansine

This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.

Latest news

NICE relents on Kadcyla after Roche pricing negotiations

The agreement comes after years of wrangling between NICE and the pharma group over the price of Kadcyla (ado-trastuzumab emtansine), which has a list price of £90, 000 a year ... older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that
A new decade of disruption: meeting the biosimilar challgenge

High price tags have seen a string of rejections for routine NHS use by the UK watchdog NICE, including cancer MAbs Avastin (bevacizumab), Kadcyla (ado-trastuzumab emtansine) and Perjeta (pertuzumab). ... An example can be seen in Roche’s introduction
Roche in "unprecedented" launch period for new medicines

The star in Roche's show was once again its trio of HER2-positive breast cancer drugs - Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - whose sales increased 9% to
Roche's melanoma combo "too expensive" for NHS use, says NICE

NICE arrived at a similar conclusion when it published a review of breast cancer drugs Perjeta (pertuzumab) in May and Kadcyla (trastuzumab-emtansine) at the end of last year.
Immunotherapy and future directions in oncology

Monoclonal antibody-based technologies have now been in use for decades targeting specific cancer cells to serve either as therapeutics (eg Genentech's trastuzumab, Herceptin) or invitro diagnostics (immunoassays) or to ... Kadcyla (trastuzumab emtansine,

More from news
Approximately 5 fully matching, plus 50 partially matching documents found.

Latest Intelligence

An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S Korea.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Director or Senior Account Director: Salary TBC

Sudler London - Account Director: Competitive

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Sudler London - Senior Medical Writer: Competitive

Senior Medical Writer, MedComms Agency: Salary TBC

Market Access Consultant - Greater Manchester: Negotiable

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Writer, Healthcare Advertising, London: Excellent package

Healthcare PR Senior Account Manager: Salary TBC

Medical Writer - Creative and Scientific Projects: DOE

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Graduate Scientific Editor: DOE

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Medical Writer: Salary is DOE

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Systematic Review Lead- London: Negotiable

Account Manager: Negotiable

Senior Account Manager – Healthcare Advertising: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....